Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 10Terminated 5Unknown 3Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 24Pancreatic Neoplasms 14Stomach Neoplasms 12Rectal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 9Esophageal Neoplasms 9Colonic Neoplasms 9Neoplasms 7Adenocarcinoma Of Esophagus 7Urinary Bladder Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Breast Neoplasms 4Anus Neoplasms 4Ovarian Neoplasms 3Nasopharyngeal Carcinoma 2Melanoma 2Hepatoblastoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Clinical Stage I Gastric Cancer AJCC v8 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Urachal cancer 1Unresectable Colorectal Cancer 1

Interventions

Gemcitabine 6Cisplatin 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Capecitabine 4Biopsy 3pembrolizumab 2durvalumab 2Trastuzumab 2Platinum 2Oxaliplatin 2Leucovorin 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2varlilumab 1tucatinib 1toripalimab 1peposertib 1guadecitabine 1dehydroftorafur 1cobimetinib 1binimetinib 1avelumab 1atezolizumab 1Tegafur 1Taxes 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Gallbladder Neoplasms × Fluorouracil × Clear all
NCT05564403 2026-05-13

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen Inc.

Phase 2 Active not recruiting
40 enrolled 67 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡